Skip to content

Application of Remimazolam Tosilate Combined with Remifentanil in Senile Cataract Surgery: a Prospective, Randomized, Controlled Study

Application of Remimazolam Tosilate Combined with Remifentanil in Senile Cataract Surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063250
Enrollment
Unknown
Registered
2022-09-02
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Interventions

Remimazolam Tosilate Group:Application of Remimazolam Tosilate Combined with Remifentanil
Propfol Group:Application of propofol combined with remifentanil

Sponsors

Beijing Huaxin Hospital (the First Affiliated Hospital of Tsinghua Uinversity)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 60-80 years; 2. To be admitted to the day ward after cataract surgery; 3. ASA grade I ~ II; 4. Estimated operation time <= 0.5h; 5. 18 kg/m2 < BMI < 30 kg/m2.

Exclusion criteria

Exclusion criteria: 1. Complicated with severe circulatory and respiratory basic diseases; 2. Difficult airway; 3. Liver and kidney dysfunction; 4. Preoperative mini mental state examination scale (MMSE) scores were consistent with dementia; 5. Mental disorder; 6. Hearing impairment; 7. Long term use of sedatives; 8. Unable to cooperate.

Design outcomes

Primary

MeasureTime frame
Wake-up time;Duration of anesthesia induction;

Secondary

MeasureTime frame
oxygen saturation;heart rate;Number of haemodynamic administrations;Bispectral index, BIS;Respiratory rate;blood pressure;Anesthesia satisfaction score;Mini-mental State Examination score;Post-Anesthesia Score;Number of assisted breaths;

Countries

China

Contacts

Public ContactJia Guangzhi

Beijing Huaxin Hospital (the First Affiliated Hospital of Tsinghua Uinversity)

jgz_606@sina.com+86 13811280761

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026